Beyond the biology of PBMCs under BCG, in the NMIBC patients, the bladder tumor expresses PD-L1 under BCG therapy [43]; therefore, the urologist’s advice is to add a PD-L1 blocker to the BCG treatment [44]. The gene discussed is CD274; the disease is urinary bladder neoplasm.